iPhone: the ultimate tool for patient empowerment.

I walk into a patient’s encounter today and he is reading Twitter on his iPhone 4. We exchanged Twitter handles and began discussing his diabetic nephropathy.

I ask how his blood sugars have been and he fires up Glucose Buddy and proceeds to show me all of his blood sugar reading since March of 2010. Then he e-mails me the data.

When we discuss blood pressure, he fires up the iPhone again and shows me iBP. When he sends me his home blood pressure readings I get the choice of receiving them as text, html or CSV. Awesome.

Glucose Buddy for the iPhone
iBP for the iPhone

Here’s is what the e-mail output looks like:

This was the first patient I have met who is using his phone to document his health. I hope this is a trend because I am sick of patients telling me that they wrote down all of their blood pressures but left the notebook at home. It’s nice to see a cell phone do something other than interrupt a clinical encounter.

Apple CEO Steve Jobs Live at D8

6:59 pm: Walt asks if Apple knew it would build a tablet before it built the iPhone.

Jobs: “I’ll tell you a secret. It began with the tablet. Jobs first charged his staff with developing a tablet, but after seeing their first efforts decided the way to go was a phone. “My God, I said, this would make a great phone … so we shelved the tablet and built the iPhone.”

iGot an iPad

I got a 3g model on Friday and I’m still trying to figure out what I’m going to use it for. How/if am I going to incorporate it into teaching.

Today we had a patient with rhabdomyolysis. The UpToDate cardClinical features and prevention of heme pigment-induced acute tubular necrosis, has this to say about bicarbonate and mannitol:

In a large series of 382 patients with serum CK concentration >5000 U/L, 154 (40 percent) were treated with bicarbonate and mannitol [33]. There was no statistically significant difference in the incidence of renal failure (creatinine >2.0 mg/dL [177 micromol/L]; 22 versus 18 percent), dialysis (7 versus 6 percent), or death (15 versus 18 percent) in patients who were or were not treated with bicarbonate and mannitol. However, there was a trend toward improved outcomes in patients with extremely high CK levels (>30,000 U/L) treated with bicarbonate and mannitol. 

Reference 33 is the primary reference for one of my first blog posts. We started talking about this study on rounds, but the crap machines in the ICU didn’t have Flash or PDF support. I ended up downloading the PDF on my iPhone and four of us passed it around to look at some of the figures. The iPad doesn’t have flash but it does a beautiful job rendering PDFs. I have the article in Papers which does an awesome job at holding and organizing my entire medical library.

Basic review of Papers

Papers is iTunes for scientific Papers. It is the modern equivalent to the file cabinet you always wanted for all the important scientific articles that fall into your grubby little hands. My computer is littered with literally hundreds of scientific articles. What you want to do is throw them all into Papers.

To understand the power of Papers, let’s look at the workflow for getting a PDF into Papers and onto the iPad. After downloading reference 33, drag it into Papers. It initially looks like this:

Then you click on Match and quickly find the article’s reference in PubMed or Google Scholar or another database. To do this I copied the author’s name and entered the year of publication.

After you double click the correct reference all of the meta-data quickly populates the appropriate fields so the you have all the data you need.
Papers even renames the original file, so your reference article folder is organized with logically named files.
To sync your library between your Mac and iPad, just run Papers on both devices simultaneously and it will synchronize your entire Library or specified subset (actually, it is limited to 1,000 articles). Syncing occurs over wifi.

On the iPad, when you launch Papers, you are in the Library.

Search on bicarbonate and you find a couple of articles on the use of bicarbonate to prevent contrast nephropathy, one on its use to treat severe metabolic acidosis, and one on its use to prevent the renal complications rhabdomyolysis…bingo!

Once you have the article you can read it in landscape with some of the meta data revealed or portrait for a more paper-like experience
Papers allows you to annotate, bookmark and share the article
 

Papers also works on the iPhone but after using it I thought it was a bit of a gimmick, I didn’t really want my PDF library on a 3.5 inch screen. The iPad makes a perfect partner for the desktop app. I’m very excited about this.

Papers for MacOS is $42.00, the iPhone/iPad application is $14.99.

PubMed on Tap for the iPhone: the NLM in your pocket

Last week at the end of a morning conferance there was an impromptu discussion of the problem of residents ordering IV contrast for patients with acute kidney injury. The residents see a patient on dialysis and feel that its open season for contrast.

As part of the discussion one of the attendings mentioned this is also a problem with his PD patients with residual renal function and the residents need to know that contrast should be avoided in these patients to preserve residual renal function. I mentioned that actually the data doesn’t support the common sense notion that contrast accelerates the loss of residual renal function. Immediately all eyes were on me and the consensus was that no one else had seen that data and that I was way off the reservation. Pretty uncomfortable place to be.

I had buttoned holed Paul Palevsky at the 2006 ASN Renal Week after a talk on contrast nephropathy and in that hallway conversation he had mentioned that he had just finished research on this vary question. he only reason I remember it was that the results were so counter intuitive. Contrast has no measurable affect on residual renal function. I had actually never seen the article but now I had put up or shut up.

After the conference I had to run to an outside hospital but I stopped at a Tim Hortons (the best thing to come out of Canada since Douglas Coupland) and fired up PubMed on Tap (PMT).

PMT is an app dedicated to adapting the PubMed database to the constraints of a mobile platform. I used an app by the same name on my old Treo. Adding Palevsky as author, and then contrast and residual renal function as text words.

Bingo! One article:

You can pull up the abstract:
The PDF:
 :
and the PubMed listing:

I then did a less specific search by dropping the author name and found a higher quality study:

I was able to send the references to my colleagues right from the application. Sweet.

iPhone, Android: Fight

Different data from the iPhone, Blackberry: Fight! from a few months ago but the same conclusion.
This battle is over! And the iPhone has won.
From Larvalabs:

Our two best selling games have been ranked and are currently ranked pretty highly on that hard to find list of paid apps. RetroDefense was #1 for a while and is currently around #12 with a perfect 5 star rating. Battle for Mars is currently #5 overall with a 4.5 star rating. Both of these games are selling for $4.99, which is on the upper end of the price range. Finally, both of these games have been featured by Google in the market app and on the Android website. So with all this in mind, here’s our daily Android sales for this August (these numbers include sales from our other two apps, but they barely register):

That’s a $62.39 daily average. Very difficult to buy the summer home at this rate.

iPhone AT&T conspiracy theory

The recent behavior of AT&T regarding the upgrade from iPhone 3G to 3GS may shed light on how long we have to wait for a second iPhone carrier in the U.S.

No one outside of AT&T and Apple know for sure the duration of AT&T’s exclusivity. In August of last year USAToday said the contract lasts until 2010 .

My thought is that if the exclusive contract ran out at the end of 2009 or by June of 2010 then AT&T would be behaving differently right now. Instead of telling people whoose contracts expire in a year to get lost for a year they would be rolling out the red carpet to extend their contract for another 2 or 3 years.

Eventually the exclusive deal will end and an early sign of that day will be AT&T offering current customers a deal to extend their contract. AT&T’s current behavior signals that the exclusivity is here for at least a couple more years.